Viloxazine hydrochloride - Supernus Pharmaceuticals

Drug Profile

Viloxazine hydrochloride - Supernus Pharmaceuticals

Alternative Names: SPN 809; SPN-812; SPN-812V; Viloxazine hydrochloride extended release - Supernus

Latest Information Update: 05 Aug 2016

Price : $50

At a glance

  • Originator Supernus Pharmaceuticals
  • Class Antidepressants; Behavioural disorder therapies; Morpholines
  • Mechanism of Action Adrenergic uptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Attention-deficit hyperactivity disorder
  • Phase I Depressive disorders

Most Recent Events

  • 02 Aug 2016 Supernus completes enrolment in its phase IIa trial for Attention deficit hyperactivity disorder (In children) in USA (NCT02633527)
  • 15 Jul 2016 Phase-I clinical trials in Depressive disorders (unspecified route) before July 2016
  • 01 Apr 2016 Phase-III clinical trials in Attention-deficit hyperactivity disorder (In children) in USA (PO) (NCT02736656)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top